Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

  • Technology appraisal guidance
  • TA321
  • Published: 

History

Review proposal consultation

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final scope (post referral)

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: final matrix

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: response to consultee and commentator comments on the draft scope and provisional matrix (post referral)

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib: draft scope - (pre referral)